Skip to Content

Insulet Corp

PODD: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$224.00YxvhdWrctcbzsc

Insulet to Benefit From Further Integration With New Continuous Glucose Monitors

Business Strategy and Outlook

With little direct competition in patch pumps, Insulet has been able to convert more users, especially patients on multiple daily injections, to its innovative, tubeless insulin pump. The firm is on the path to meaningful profitability gains.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of PODD so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center